At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 124 enrolled
Drug / intervention
BNT162b2biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A PHASE 2b, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF VACCINE CANDIDATE BNT162b2 IN IMMUNOCOMPROMISED PARTICIPANTS ≥2 YEARS OF AGE
In Brief
A Phase 2 clinical trial evaluating BNT162b2 for SARS-CoV-2 Infection, COVID19. Completed, enrolled 124 participants across 29 sites in 4 countries.
Detailed Summary
This is a 4 dose study with 124 participants (7 adults ,117 children). Adults are considered to be participants 18 years of age or older. Participants are going to be enrolled based on conditions that make them immunocompromised. Participants are going to be followed up for 6 months after dose 4, and each participant is projected to be on the study for approximately 15 months. This study will be conducted in the United States, Brazil, Germany and Mexico.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSARS-CoV-2 Infection, COVID19
CountriesBrazil, Germany, Mexico, United States
CollaboratorsPfizer
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedMay 2021
Enrollment StartOct 2021
Primary CompletionJul 2023
TodayJul 2026
First PostedMay 21, 2021
Enrollment StartOct 15, 2021
Primary CompletionJul 23, 2023
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 5.1 years ago
Interventions
BNT162b2biological
Intramuscular Injection